Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco from January 13-16, 2025.

Dr. Taylor Schreiber, CEO of Shattuck, will deliver a corporate update presentation on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in the Elizabethan B room. The presentation will be available via live webcast on the company's website, with a replay accessible for up to 30 days afterward.

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43^rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025.

Conference Details
Format: Presentation and one-on-one meetings
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: January 16, 2025
Time: 7:30 a.m. PT
Location: The Westin St. Francis, San Francisco, California
Room: Elizabethan B

A live webcast of the presentations will be available on the Events and Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. 

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

When is Shattuck Labs (STTK) presenting at the 2025 J.P. Morgan Healthcare Conference?

Shattuck Labs will present on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in San Francisco.

How long will STTK's J.P. Morgan Healthcare Conference presentation replay be available?

The webcast replay will be archived and available for up to 30 days following the presentation date.

What is the focus of Shattuck Labs' (STTK) therapeutic development?

Shattuck Labs focuses on developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for treating inflammatory and immune-related diseases.

Where can investors watch Shattuck Labs' (STTK) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast through the Events and Presentations section of the Company's website.